BGB-43395 + Letrozole for Breast Cancer

(KANDELA-302 Trial)

This trial tests a new treatment combination for individuals with advanced or metastatic breast cancer that is hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). The study aims to evaluate the effectiveness of the new drug, BGB-43395, in combination with letrozole, compared to other common treatments that include a cyclin-dependent kinase 4/6 inhibitor (a type of cancer-fighting drug) with letrozole. Individuals who have not received treatment for their advanced cancer and have a stable condition might be suitable candidates. The goal is to determine which treatment option is more effective and safer for managing this type of breast cancer. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that combining BGB-43395 with letrozole is generally safe. Most side effects reported in studies were mild to moderate. One study found that 93.8% of patients experienced side effects related to BGB-43395, but these were mostly mild, indicating the treatment is usually well-tolerated.

For the other treatments in this trial—abemaciclib, palbociclib, and ribociclib—when used with letrozole, research has also shown they are safe. These treatments did not reveal any new safety issues and were generally well-tolerated by breast cancer patients.

Researchers are excited about these treatments because they offer new approaches for tackling breast cancer. BGB-43395 is unique as it is being combined with letrozole to potentially provide a novel mechanism of action that targets cancer cells differently compared to standard treatments like abemaciclib, palbociclib, and ribociclib, which are all cyclin-dependent kinase 4/6 inhibitors. This combination may enhance the effectiveness of letrozole by working in tandem to disrupt cancer cell growth. Meanwhile, the combination of letrozole with existing options like abemaciclib, palbociclib, or ribociclib allows researchers to explore the best possible synergy between these drugs, offering hope for more effective and personalized treatment strategies for patients with breast cancer.

Research shows that the combination of BGB-43395 and letrozole, administered to participants in Arm A of this trial, may effectively treat advanced hormone receptor-positive breast cancer. Early studies found that this combination had a response rate of up to 68.4%, significantly affecting cancer activity markers. In Arm B, participants will receive a cyclin-dependent kinase 4/6 inhibitor (either abemaciclib, palbociclib, or ribociclib) with letrozole. Studies on these drugs, when combined with letrozole, also show positive results, with response rates between 62.5% and 64.2%. These findings suggest that both treatment options in this trial can effectively manage this type of breast cancer.²³⁶⁷⁸